Listeria Balanced Lethal Systems Expressing Cervical Cancer Antigen Genes: Construction and Basic Biological Characteristics

OU Qian, CHEN Zhaobin, TANG Jing, CHEN Mengdie, ZHANG Yunwen, WANG Chuan

Abstract

To construct Listeria monocytogenes (LM) and Listeria ivanovii (LI) balanced lethal systems expressing cervical cancer antigens, to study their basic biological characteristics, and to provide reference data for the immunotherapy of cervical cancer.  Methods  Through seamless cloning via in vitro ligation kit, the HPV16 E6E7 fusion protein antigen gene constructed in our lab was spliced to the complement plasmid pCWgfp-LM dal-Amp that contained the nutritional gene dal. Then, we replaced the ampicillin (Amp) resistance gene of the complement plasmid with the asd nutrition gene. The ligation reaction mixture was transformed into Escherichia coli (E. coli) recipient bacteria DH5αΔasd and the complement plasmid pCWgfp-E6E7-LM dal-Ampfree, which expressed cervical cancer antigens and had no Amp resistance, was obtained by nutrition screening from the E. coli DH5αΔasd. The plasmid pCWgfp-E6E7-LM dal-Ampfree was complemented into LMΔdd and LIΔdd, the attenuated nutrition-deficient Listeria strains with the virulence genes actA and plcB and nutrition genes dal and dat deleted by electroporation, thereby obtaining LM and LI balanced lethal systems expressing cervical cancer antigen genes. The in vitro growth of the strains was observed. Western blot was performed to examine the status of antigen protein expression. PCR was performed to measure the in vitro passage stability of complement plasmid pCWgfp-E6E7-LM dal-Ampfree. Their basic biological characteristics were examined by biochemical reaction tests and hemolysis assay.  Results  Two Listeria balanced lethal systems expressing cervical cancer antigen were successfully constructed. The HPV16 type E6E7 fusion protein was successfully expressed in the two Listeria balanced lethal systems. pCWgfp-E6E7-LM dal-Ampfree, the positive plasmid expressing cervical cancer antigen, maintained stable existence in the two Listeria balanced lethal systems. The two Listeria balanced lethal systems expressing cervical cancer antigen showed significantly better recovery growth in comparison with Listeria nutrition deficiency strains. The results of biochemical reaction tests showed that most of the biochemical reaction of the two Listeria balanced lethal systems expressing cervical cancer antigen were consistent with those of Listeria attenuated strains. The two Listeria balanced lethal systems expressing cervical cancer antigen still maintained the hemolytic ability, although their hemolytic ability was slightly inferior to that of the Listeria balanced lethal systems not expressing cervical cancer antigen and the Listeria attenuated strains.  Conclusion  The two Listeria balanced lethal systems expressing cervical cancer antigen genes are constructed successfully. They display normal in vitro growth. The complement plasmid pCWgfp-E6E7-LM dal-Ampfree can maintain stable existence in vitro, showing little change in its biochemical characteristics and hemolytic ability. Further research should be conducted to investigate the potential of these two recombinant strains to be used as candidate strains for cervical cancer therapeutic vaccine.

 

Keywords: Cervical cancer,  Balanced lethal system,  Listeria

 

Full Text:

PDF


References


SIEGEL R L， MILLER K D， FUCHS H E， et al. Cancer statistics, 2022. CA Cancer J Clin，2022，72(1): 7–33. doi: 10.3322/caac.21708.

TOUSSAINT B， CHAUCHET X， WANG Y， et al. Live-attenuated bacteria as a cancer vaccine vector. Expert Rev Vaccines，2013，12(10): 1139–1154. doi: 10.1586/14760584.2013.836914.

GLUSCHKO A， FARID A， HERB M， et al. Macrophages target Listeria monocytogenes by two discrete non-canonical autophagy pathways. Autophagy，2022，18(5): 1090–1107. doi: 10.1080/15548627.2021. 1969765.

LIANG Z Z， SHERRID A M， WALLECHA A， et al. Listeria monocytogenes: a promising vehicle for neonatal vaccination. Hum Vaccin Immunother，2014，10(4): 1036–1046. doi: 10.4161/hv.27999.

BRUHN K W， CRAFT N， MILLER J F. Listeria as a vaccine vector. Microbes Infect，2007，9(10): 1226–1235. doi: 10.1016/j.micinf.2007.05. 010.

MITCHELL G， GE L， HUANG Q Y， et al. Avoidance of autophagy mediated by PlcA or ActA is required for Listeria monocytogenes growth in macrophages. Infect Immun，2015，83(5): 2175–2184. doi: 10.1128/IAI. 00110-15.

FLICKINGER J C， Jr， RODECK U， SNOOK A E. Listeria monocytogenes as a vector for cancer immunotherapy: current understanding and progress. Vaccines，2018，6(3): 48. doi: 10.3390/vaccines6030048.

WIELSTRA B. Balanced lethal systems. Curr Biol，2020，30(13): R742–R743. doi: 10.1016/j.cub.2020.05.011.

LEI Y， ZHOU Y， ZHANG Y， et al. A Listeria ivanovii balanced-lethal system may be a promising antigen carrier for vaccine construction. Microb Biotechnol，2022，15(11): 2831–2844. doi: 10.1111/1751-7915. 14137.

CHEN Y， YANG D， LI S， et al. Development of a Listeria monocytogenes-based vaccine against hepatocellular carcinoma. Oncogene，2012，31(17): 2140–2152. doi: 10.1038/onc.2011.395.

SU L， ZHANG Y， ZHANG X， et al. Combination immunotherapy with two attenuated Listeria strains carrying shuffled HPV-16 E6E7 protein causes tumor regression in a mouse tumor model. Sci Rep，2021，11(1): 13404. doi: 10.1038/s41598-021-92875-9.

YAN Y， MU W， ZHANG L， et al. Asd-based balanced-lethal system in attenuated Edwardsiella tarda to express a heterologous antigen for a multivalent bacterial vaccine. Fish Shellfish Immunol，2013，34(5): 1188–1194. doi: 10.1016/j.fsi.2013.01.027.

THOMPSON R J， BOUWER H G， PORTNOY D A， et al. Pathogenicity and immunogenicity of a Listeria monocytogenes strain that requires D-alanine for growth. Infect Immun，1998，66(8): 3552–3561. doi: 10.1128/IAI.66.8.3552-3561.

WALLECHA A， MACIAG P C， RIVERA S， et al. Construction and characterization of an attenuated Listeria monocytogenes strain for clinical use in cancer immunotherapy. Clin Vaccine Immunol，2009，16(1): 96–103. doi: 10.1128/CVI.00274-08.

QUISPE-TINTAYA W， CHANDRA D， JAHANGIR A， et al. Nontoxic radioactive Listeriaat is a highly effective therapy against metastatic pancreatic cancer. Proc Natl Acad Sci U S A，2013，110(21): 8668–8673. doi: 10.1073/pnas.1211287110.

BOLHASSANI A， NADERI N， SOLEYMANI S. Prospects and progress of Listeria-based cancer vaccines. Expert Opin Biol Ther，2017，17(11): 1389–1400. doi: 10.1080/14712598.2017.1366446.

WAN X， CHENG C， LIN Z， et al. The attenuated hepatocellular carcinoma-specific Listeria vaccine Lmdd-MPFG prevents tumor occurrence through immune regulation of dendritic cells. Oncotarget， 2015，6(11): 8822–8838. doi: 10.18632/oncotarget.3558.

MASON N J， GNANANDARAJAH J S， ENGILES J B， et al. Immunotherapy with a HER2-targeting Listeria induces HER2-specific immunity and demonstrates potential therapeutic effects in a phase I trial in canine osteosarcoma. Clin Cancer Res，2016，22(17): 4380–4390. doi: 10.1158/1078-0432.CCR-16-0088.

VERCH T， PAN Z K， PATERSON Y. Listeria monocytogenes-based antibiotic resistance gene-free antigen delivery system applicable to other bacterial vectors and DNA vaccines. Infect Immun，2004，72(11): 6418–6425. doi: 10.1128/IAI.72.11.6418-6425.2004.


Refbacks

  • There are currently no refbacks.